Companies › argenx
7 active drug programs in 38 registered trials: 18 Phase 2, 11 Phase 3, 6 Phase 1, 3 Phase 4; Other, Neurology, Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Efgartigimod Alfa (PH20) IgG receptor FcRn large subunit p51 antagonist | FCGRT | Phase 4 | New Onset Generalized Myasthenia Gravis (gMG); Primary Sjogrens Disease; Primary Immune Thrombocytopenia; Myasthenia Gravis, Ocular … | Mar 2027 |
| Empasiprubart FcRn antagonist | FCRN, FCRL5 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis … | Nov 2026 |
| ARGX-119 DOK7-targeted therapy for congenital myasthenic syndrome | – | Phase 2 | Spinal Muscular Atrophy (SMA); Congenital Myasthenic Syndrome | Aug 2027 |
| ARGX-117 FcγRIIB agonist / IgG4-Fc fusion protein | FCGR2B | Phase 2 | Multifocal Motor Neuropathy (MMN); Delayed Graft Function | Sep 2029 |
| ARGX-121 IgA immune complex inhibitor; blocks FcαRI signaling pathway | FCAR | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Oct 2029 |
| Adimanebart | – | Phase 1 | Healthy Volunteers (HV) | Dec 2026 |
| ARGX-124 | – | Phase 1 | Healthy Volunteers | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07782775 | Efgartigimod Alfa (PH20) | Phase 1 | Healthy Volunteer | Other | Sep 2026 |
| NCT06284954 | Empasiprubart | Phase 2 | Dermatomyositis | Immunology | Nov 2026 |
| NCT07673601 | Adimanebart | Phase 1 | Healthy Volunteers (HV) | Other | Dec 2026 |
| NCT06860633 | Efgartigimod Alfa (PH20) | Phase 4 | Myasthenia Gravis Crisis | Neurology | Dec 2026 |
| NCT07377396 | ARGX-124 | Phase 1 | Healthy Volunteers | Other | Dec 2026 |
| NCT06765161 | Efgartigimod Alfa (PH20) | Phase 3 | Myasthaenia Gravis | Neurology | Jan 2027 |
| NCT04833894 | Efgartigimod Alfa (PH20) | Phase 2 | Generalized Myasthenia Gravis | Neurology | Mar 2027 |
| NCT06655155 | Efgartigimod Alfa (PH20) | Phase 2 | Systemic Sclerosis (SSc) | Immunology | Mar 2027 |
| NCT07612020 | Empasiprubart | Phase 1 | Healthy Volunteers | Other | Mar 2027 |
| NCT04280718 | Efgartigimod Alfa (PH20) | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Neurology | Apr 2027 |
| NCT06909214 | Efgartigimod Alfa (PH20) | Phase 4 | New Onset Generalized Myasthenia Gravis (gMG) | Neurology | May 2027 |
| NCT06453694 | Efgartigimod Alfa (PH20) | Phase 2 | Optic Neuritis | Neurology | Jun 2027 |
| NCT06684847 | Efgartigimod Alfa (PH20) | Phase 3 | Primary Sjogrens Disease | Immunology | Jul 2027 |
| NCT06436742 | ARGX-119 | Phase 1 | Congenital Myasthenic Syndrome | Neurology | Aug 2027 |
| NCT06392386 | Efgartigimod Alfa (PH20) | Phase 2 | Generalized Myasthenia Gravis | Neurology | Sep 2027 |
| NCT06920004 | Empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Sep 2027 |
| NCT07072988 | Efgartigimod Alfa (PH20) | Phase 4 | Myasthenia Gravis, Generalized | Neurology | Oct 2027 |
| NCT07091630 | Empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Oct 2027 |
| NCT04812925 | Efgartigimod Alfa (PH20) | Phase 3 | Primary Immune Thrombocytopenia | Hematology | Oct 2027 |
| NCT07673627 | Empasiprubart | Phase 2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Neurology | Oct 2027 |
| NCT06503731 | Efgartigimod Alfa (PH20) | Phase 2 | Antibody-mediated Rejection | Other | Nov 2027 |
| NCT06558279 | Efgartigimod Alfa (PH20) | Phase 3 | Myasthenia Gravis, Ocular | Neurology | Dec 2027 |
| NCT07822776 | Efgartigimod Alfa (PH20) | Phase 2 | Encephalitis Autoimmune | Immunology | Dec 2027 |
| NCT07610564 | Empasiprubart | Phase 1 | Multifocal Motor Neuropathy (MMN) | Neurology | Feb 2028 |
| NCT07025330 | Efgartigimod Alfa (PH20) | Phase 2 | IgG4-related Disease | Other | Mar 2028 |
| NCT07284420 | Efgartigimod Alfa (PH20) | Phase 2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Neurology | Mar 2028 |
| NCT07284420 | Empasiprubart | Phase 2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | Neurology | Mar 2028 |
| NCT06831058 | Efgartigimod Alfa (PH20) | Phase 2 | Immune-mediated Thrombotic Thrombocytopenic Purpura | Hematology | May 2028 |
| NCT07570316 | Efgartigimod Alfa (PH20) | Phase 3 | Graves' Disease | Metabolic and endocrine | Jun 2028 |
| NCT07596849 | Efgartigimod Alfa (PH20) | Phase 3 | Graves Disease | Metabolic and endocrine | Jun 2028 |
| NCT06544499 | Efgartigimod Alfa (PH20) | Phase 3 | Primary Immune Thrombocytopenia (ITP) | Hematology | Jun 2028 |
| NCT06298552 | Efgartigimod Alfa (PH20) | Phase 3 | Generalized Myasthenia Gravis | Neurology | Jun 2028 |
| NCT07194850 | Efgartigimod Alfa (PH20) | Phase 2 | Immune Thrombocytopenia (ITP) | Hematology | Oct 2028 |
| NCT07287982 | ARGX-119 | Phase 2 | Spinal Muscular Atrophy (SMA) | Neurology | May 2029 |
| NCT05405361 | ARGX-117 | Phase 2 | Multifocal Motor Neuropathy (MMN) | Neurology | Sep 2029 |
| NCT07773727 | ARGX-121 | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Genitourinary | Oct 2029 |
| NCT06742190 | Empasiprubart | Phase 3 | Multifocal Motor Neuropathy (MMN) | Neurology | Dec 2029 |
| NCT05907096 | ARGX-117 | Phase 2 | Delayed Graft Function | Other | May 2030 |
Nuvig Therapeutics Zenas BioPharma (USA) BioInvent International Johnson & Johnson (Janssen) Sanofi UCB Biopharma SRL Immunovant Sciences
Pharmazz Keymed Biosciences Co.Ltd Chongqing Claruvis Pharmaceutical Harmony Biosciences Management Merz Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.